Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04533828
Status:
UNKNOWN
Last Update Posted:
2020-09-03
First Post:
2020-08-22
Brief Title:
68Ga-FAPI PETCT in Liver Fibrosis Patients
Sponsor:
First Affiliated Hospital of Fujian Medical University
Organization:
First Affiliated Hospital of Fujian Medical University
Study Overview
Official Title:
Value of 68Ga-FAPI-04 PETCT for Diagnosis and Prognostic Evaluation in Liver Fibrosis
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GFAPILF
Brief Summary:
To evaluate the potential value of 68Ga-FAPI-04 positron emission tomographycomputed tomography PETCT for the diagnosis and prognosis in liver fibrosis disease
Detailed Description:
Subjects with liver fibrosis underwent 68Ga-FAPI-04 PETCT scanning Liver fibrosis lesion uptake was quantified by the maximum standard uptake value SUVmax Subjects also received the conventional clinical assessment for liver fibrosis such as transient elastography TE and blood biochemical indexes BBI testing The sensitivity specificity positive predictive value PPV negative predictive value NPV and accuracy of 68Ga-FAPI-04 PETCT TE and BBI were calculated and compared to evaluate the diagnostic efficacy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None